T&RBiofab
Biotechnology Research • 
237 Sangidaehak-ro, #542, Korea, Republic of • 21-50 Employees
Company overview
| Headquarters | 237 Sangidaehak-ro, #542, Smart-Hub Industry-University Convergence Center, Gyeonggi-do, 15073, KR |
| Website | |
| NAICS | 541714 |
| SIC | 873 |
| Keywords | Biomaterials, Tissue Engineering, Bioprinting, Scaffold, Bioink, Patient Specific Implant, iPS |
| Founded | 2013 |
| Employees | 21-50 |
| Socials |
Key Contacts at T&RBiofab
Won-Soo Yun
Chief Executive Officer
Young Phill Kim
Senior Managing Director / Cfo
T&RBiofab Email Formats
T&RBiofab uses 2 email formats. The most common is {first name} (e.g., john@tnrbiofab.com), used 50% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name} | john@tnrbiofab.com | 50% |
{first name}{last name} | johndoe@tnrbiofab.com | 50% |
About T&RBiofab
T&R Biofab is a science-driven and product-oriented company which has developed and produced their own 3D Bio-printing System for the creation of biodegradable scaffolds, Bio-ink, 3D Organoid Models, Cytotherapeutic Agents, and Artificial Organs At the beginning, T&R Biofab started its business with the development of 3D Bio-printing equipment. At that time, T&R recognized that there were lots of promises on the bioprinting field that would need a consistent development to make it become a reality, and the use of other cutting-edge technologies such as biomimetic biomaterials and pluripotent stem cells would help to achieve these promises. Currently, after securing key IP, filing over 100 patents, and expanding our area of research, using iPS cells and special biomaterials; T&R has the core technology to develop artificial organs such as skin, heart, and liver, having publications on the most renown scientific journals of the world (Biofabrication, Biomaterials, Small, Nature Communications, Advanced Materials, etc.) The CEO, Dr. Wonsoo Yun, set T&R’s major goal as to change people’s life through relieving the pain of the ones in need. This dream is being achieved using our proprietary biomedical solutions and innovative thinking. Partnering with key players, T&R is reaching more patients making: patient specific implants for reconstruction of damaged areas of the face, cranio-maxillofacial mesh to repair or smooth defects from surgeries, among other confidential applications (in development under CDA). T&R has an increasing interest in organ reconstruction (liver) and cell therapy applications (CAR T, Cardio), and we hope you will join T&R Biofab on our journey to change the biomedical world. #TnRBiofab #TissueEngineering #Healthcare #Bioprinting #MedicalDevices #CellTherapy
T&RBiofab revenue & valuation
| Annual revenue | $2,566,650 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $8,300,000 |
| Total funding | No funding |
Employees by Management Level
Total employees: 21-50
Seniority
Employees
Employees by Department
T&RBiofab has 9 employees across 6 departments.
Departments
Number of employees
T&RBiofab Tech Stack
Discover the technologies and tools that power T&RBiofab's digital infrastructure, from frameworks to analytics platforms.
Web servers
United Kingdom
Spain
United States
Frequently asked questions
4.8
40,000 users
